Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Share on facebook
Share on twitter
Share on linkedin

March 2019: BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia

MORRISTOWN, NJ (March 18, 2019). BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients requiring hospitalization because of Community-Acquired Pneumonia (CAP).

A Novel Approach to Create a New Treatment Paradigm

Severe CAP is the lead indication of this clinical-stage company that addresses infectious, inflammatory and degenerative diseases with supplementation of an endogenous protein that is depressed in these disorders.

Patients were treated with recombinant human plasma gelsolin (rhu-pGSN) or a matching placebo in this blinded randomized clinical trial.

Read the full press release here: 2019 03 18 Completes Enrollment Phase 1b_2a